PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses

Pharmacotherapy

Volumn 36, Issue 3, 2016, Pages 317-334

  Medina, Patrick J ^a   Adams, Val R ^b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

adverse event; cancer; immune checkpoint blockade; immuno oncology; oncology; PD 1; programmed death 1 pathway

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; BIOLOGICAL MARKER; CYTOCHROME P450; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DOCETAXEL; DURVALUMAB; IPILIMUMAB; NIVOLUMAB; PD1 INHIBITOR; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE MYELOBLASTIC LEUKEMIA; ADVANCED CANCER; ANUS CANCER; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COLITIS; COLON CANCER; COLORECTAL CARCINOMA; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; ENDOCRINE DISEASE; ESOPHAGUS CANCER; EVIDENCE BASED MEDICINE; GASTROINTESTINAL DISEASE; GLIOBLASTOMA; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOPATHOLOGY; INFUSION RELATED REACTION; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY METASTASIS; LIVER DISEASE; LUNG DISEASE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MERKEL CELL TUMOR; MULTIPLE MYELOMA; NASOPHARYNX CARCINOMA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROSTATE CANCER; PROTEIN FUNCTION; PRURITUS; QUALITY OF LIFE; RASH; REVIEW; SARCOMA; SKIN DISEASE; STOMACH CANCER; THYMUS CANCER; TRANSITIONAL CELL CARCINOMA; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; DRUG EFFECTS; IMMUNOLOGY; IMMUNOMODULATION; NEOPLASMS; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; HUMANS; IMMUNOMODULATION; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84961677991     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1714     Document Type: Review

References (63)

1. Yervoy (ipilimumab) prescribing information. Princeton, NJ: Bristol-Myers Squibb; 2015.
2. Keytruda (pembrolizumab) prescribing information. Whitehouse Station, NJ: Merck & Co; 2015.
3. Opdivo (nivolumab) prescribing information. Princeton, NJ: Bristol-Myers Squibb; 2015.
4. Wang C, Thudium KB, Han M, et al., In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2014; 2: 846-56.
5. Robert C, Ribas A, Wolchok JD, et al., Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384: 1109-17.
6. Rizvi NA, Brahmer JR, Ou S-HI, et al., Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC) [abstract 8032]. J Clin Oncol 2015; 33 (Suppl). Available from http://meetinglibrary.asco.org/content/108561?media=sl. Accessed July 14, 2015.
7. Powles T, Eder JP, Fine GD, et al., MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515: 558-62.
8. Berger R, Rotem-Yehudar R, Slama G, et al., Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14: 3044-51.
9. Pardoll DM,. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64.
10. + T cell adoptive immunotherapy. Immunity 2000; 13: 265-76.
11. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 2005; 102: 9571-6.
12. + T cells: A common basis between tumor immunity and autoimmunity. J Immunol 1999; 163: 5211-8.
13. Sharma P, Allison JP,. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015; 161: 205-14.
14. Fife BT, Bluestone JA,. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008; 224: 166-82.
15. Taube JM, Klein AP, Brahmer JR, et al., Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014; 20: 5064-74.
16. Zou W, Chen L,. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8: 467-77.
17. Baksh K, Weber J,. Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations. Semin Oncol 2015; 42: 363-77.
18. + T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 2010; 7: 389-95.
19. Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ,. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol 2012; 2012: 656340.
20. Peng W, Liu C, Xu C, et al., PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res 2012; 72: 5209-18.
21. Zhou Q, Xiao H, Liu Y, et al., Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol 2010; 185: 5082-92.
22. U.S. Food and Drug Administration. Medical Reviewers Report Product: Proleukin (aldesleukin), Proleukin, interleukin-2 (IL-2). Available from http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm094495.pdf. Accessed August 6, 2015.
23. Topalian SL, Sznol M, McDermott DF, et al., Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020-30.
24. Weber JS, D'Angelo SP, Minor D, et al., Nivolumab compared with chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 therapy. Lancet Oncol 2015; 16: 375-84.
25. Robert C, Long GV, Brady B, et al., Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-30.
26. Postow MA, Chesney J, Pavlick AC, et al., Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006-17.
27. Robert C, Schachter J, Long GV, et al., Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 30-9.
28. Atkins MB, Kudchadkar RR, Sznol M, et al., Pidilizumab in metastatic melanoma; results from a multicenter phase II, open label randomized trial [abstract 9001]. J Clin Oncol 2014; 32 (5s).
29. Rizvi NA, Mazières J, Planchard D, et al., Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol 2015; 16: 257-65.
30. Brahmer J, Reckamp KL, Baas P, et al., Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-35.
31. Borghaei H, Paz-Ares L, Horn L, et al., Nivolumab versus docetaxel in advanced non-squamous non-small-cell lung cancer. N Engl J Med 2015; 373: 1627-39.
32. Garon EB, Rizvi NA, Hui R, et al., Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 21 (372): 2018-28.
33. Herbst RS, Baas P., Kim D-W, et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. N Engl J Med 2015 >. Epub ahead of print 19 December. http://dx.doi.org/10.1016/S0140-6736(15)01281-7.
34. Motzer R, Rini B, McDermott D, et al., Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2015; 33: 1430-7.
35. Plimack ER, Hammers HJ, Rini BI, et al., Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC) [abstract 4533]. J Clin Oncol 2015; 33 (Suppl).
36. Motzer RJ, Escudier B, McDermott DF, et al., Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373: 1803-13.
37. Ribas A, Puzanov I, Dummer R, et al., Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16: 908-18.
38. Rizvi NA, Hellmann MD, Snyder A, et al., Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348: 124-8.
39. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-25.
40. Gettinger SN, Horn L, Gandhi L, et al., Overall survival and long-term safety of nivolumab (anti-PD-1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015; 33: 2004-12.
41. Sunshine J, Taube JM,. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 2015; 23: 32-8.
42. Larkin J, Chiarion-Sileni V, Gonzalez R, et al., Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34.
43. Hammers HJ, Plimack ER, Infante JR, et al., Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC) [abstract 4516]. J Clin Oncol 2015; 33 (Suppl). Available from http://meetinglibrary.asco.org/content/109741?media=sl. Accessed July 14, 2015.
44. Calvo E, López-Martin JA, Bendell J, et al., Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC), European Cancer Congress. Vienna, Austria, 2015. Available from http://poster-submission.com/ecc2015. Accessed November 10, 2015.
45. Hellmann MD, Rizvi NA, Gettinger SN, et al., Safety and efficacy of first-line nivolumab and ipilimumab in non-small cell lung cancer (NSCLC), European Cancer Congress. Vienna, Austria, 2015. Available from http://poster-submission.com/ecc2015. Accessed November 10, 2015.
46. Gettinger SN, Hellmann MD, Shepherd FA, et al., First-line monotherapy with nivolumab in advanced non-small cell lung cancer (NSCLC): safety, efficacy, and biomarker analyses, European Cancer Congress. Vienna, Austria, 2015. Available from http://poster-submission.com/ecc2015. Accessed November 10, 2015.
47. Herbst RS, Soria JC, Kowanetz M, et al., Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-7.
48. McDermott DF, Drake CG, Sznol M, et al., Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 2015; 33: 2013-20.
49. Hodi FS, Ribas A, Daud A, et al., Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475 [abstract 3006]. J Clin Oncol 2014; 32 (5s). Available from http://meetinglibrary.asco.org/content/94752?media=vm. Accessed July 14, 2015.
50. Wolchok JD, Hoos A, O'Day S, et al., Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-20.
51. Hodi FS, O'Day SJ, McDermott DF, et al., Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
52. Ribas A, Hodi FS, Kefford R, et al., Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL) [abstract LBA9000]. J Clin Oncol 2014; 32 (5s): Available from http://meetinglibrary.asco.org/content/93504?media=sl. Accessed July 14, 2015.
53. Leighl N, Gandhi L, Hellmann MD, et al., Pembrolizumab for NSCLC: immune-mediated adverse events and corticosteroid use, 16th World Conference on Lung Cancer. Denver, CO, USA, 2015. Available from http://library.iaslc.org/virtual-library. Accessed November 10, 2015.
54. Christensen H, Hermann M,. Immunological response as a source to variability in drug metabolism and transport. Front Pharmacol 2012; 3: 8.
55. Passey C, Simon J, Hong Q, Roy A, Agrawal S,. Assessment of drug interaction potential by nivolumab using cytokine modulation data. Clin Pharm Ther 2015; 97 (Suppl 1): S96.
56. Agrawal S, Roy A, Feng Y, et al., Immunogenicity of nivolumab and its impact on pharmacokinetics and safety in subjects with metastatic solid tumors. Clin Pharm Ther 2015; 97 (Suppl 1): S95.
57. Le DT, Uram JN, Wang H, et al., PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509-20.
58. Patnaik A, Kang SP, Rasco D, et al., Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. J Clin Oncol 2015; 21: 4286-93.
59. Barzey V, Atkins MB, Garrison LP, Asukai Y, Kotapati S, Penrod JR,. Ipilimumab in 2nd line treatment of patients with advanced melanoma: A cost-effectiveness analysis. J Med Econ 2013; 16: 202-12.
60. Ubel PA, Hirth RA, Chernew ME, Fendrick AM,. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003; 163: 1637-41.
61. Fellner C,. Ipilimumab (Yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. P T 2012; 37: 503-30.
62. Schnipper LE, Davidson NE, Wollins DS, et al., American Society of Clinical Oncology statement: A conceptual framework to assess the value of cancer treatment options. J Clin Oncol 2015; 33: 2563-77.
63. Segal NH, Ou S-HI, Balmanoukian AS, et al., Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort [abstract 3011]. J Clin Oncol 2015; 33 (Suppl). Available from http://meetinglibrary.asco.org/content/110673?media=sl. Accessed July 14, 2015.